戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  a more important role in thrombosis than in haemostasis.
2  that they play diverse roles beyond that of haemostasis.
3 elation between sheath size and unsuccessful haemostasis.
4 luding thrombosis, angiogenesis and vascular haemostasis.
5  the International Society on Thrombosis and Haemostasis.
6 xity of the biochemical reactions underlying haemostasis.
7 metabolism, cardiovascular homoeostasis, and haemostasis.
8  the International Society on Thrombosis and Haemostasis.
9 s essential for transport, inflammation, and haemostasis.
10 2) modulates platelet activation to regulate haemostasis.
11 cular injury without affecting parameters of haemostasis.
12 ecting the critical function of platelets in haemostasis.
13  the International Society on Thrombosis and Haemostasis.
14 ine protease thrombin is a critical event in haemostasis.
15 grins have a critical role in thrombosis and haemostasis.
16 , II, and III, which is essential for normal haemostasis.
17 is critical for understanding thrombosis and haemostasis.
18 form a plug which is responsible for primary haemostasis.
19 ma fibrinogen concentrations are critical to haemostasis.
20 oprotein essential for primary and secondary haemostasis.
21 ght reduce thrombosis with minimal effect on haemostasis.
22                        High effectiveness of haemostasis (98%) was observed in the study group, with
23                        High effectiveness of haemostasis (98%), low percentage of short- and mid-term
24            In addition, the effectiveness of haemostasis after a percutaneous procedure and the numbe
25 tment approaches include early diagnosis and haemostasis, aggressive management of blood pressure, op
26 on and the Spanish Society of Thrombosis and Haemostasis aimed to achieve consensus regarding the ind
27 e genetic regulation of proteins involved in haemostasis and atherothrombotic disorders, including my
28  flow conditions and achieve wound-triggered haemostasis and decreased bleeding times in vivo in a tr
29 the distinct roles of individual agonists in haemostasis and have important consequences in the desig
30                    Platelets are critical in haemostasis and in arterial thrombosis, which causes hea
31 he third in a series on interactions between haemostasis and inflammation.
32 tivation by thrombin is necessary for normal haemostasis and may be an important target in the treatm
33 va that degrade nucleotides, thus inhibiting haemostasis and minimizing the ensuing pain and inflamma
34                         We further performed haemostasis and platelet depletion tests in the R6/2 HD
35 on at early stages is crucial for preserving haemostasis and reducing the likelihood of ischaemic ath
36                         Understanding normal haemostasis and the pathophysiology of its disorders is
37  as apolipoprotein H, has been implicated in haemostasis and the production of anti-phospholipid anti
38  the International Society of Thrombosis and Haemostasis and their associations with the occurrence o
39 derlie a potential role of microparticles in haemostasis and thrombosis as modulators of fibrin forma
40  Improved understanding of the mechanisms of haemostasis and thrombosis has revealed new targets for
41 rtance of platelet activation by thrombin in haemostasis and thrombosis is unknown.
42          This Review provides an overview of haemostasis and thrombosis, details the current landscap
43    Roles for PARs are beginning to emerge in haemostasis and thrombosis, inflammation, and perhaps ev
44                                           In haemostasis and thrombosis, platelet, coagulation and an
45  importance of circulating microparticles in haemostasis and thrombosis, there is limited evidence fo
46   Tissue factor (TF) plays a central role in haemostasis and thrombosis.
47 ower on the modulation of platelet function, haemostasis and thrombosis.
48 g platelet function, thereby contributing to haemostasis and thrombosis.
49 ates platelets is critical for understanding haemostasis and thrombosis.
50 Platelets undoubtedly play a pivotal role in haemostasis and trauma-induced coagulopathy.
51 te cytoplasm, have a critical role in normal haemostasis, and in thrombotic disorders.
52  a crucial role in the maintenance of normal haemostasis, and perturbations of this system can lead t
53 t activation during inflammation compared to haemostasis, and that hitherto undiscovered platelet act
54           The primary endpoint was effective haemostasis, and the co-primary endpoint was rapid INR r
55              Genes influencing activation of haemostasis are likely to be an important component of t
56 is system may be compromised by disorders of haemostasis associated with a prothrombotic state, we po
57 result in a further deterioration of primary haemostasis at the level of varix.
58 els, International Society of Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH BAT) confirme
59  the International Society on Thrombosis and Haemostasis bleeding assessment tool.
60      International Society on Thrombosis and Haemostasis bleeding was a secondary safety outcome.
61 STH (International Society on Thrombosis and Haemostasis) bleeding classifications was assessed in 2,
62              Factor XI plays a minor role in haemostasis but contributes substantially to thrombus ex
63 vital role in preventing haemorrhage through haemostasis, but complications arise when platelets beco
64 ve long been known for their role in primary haemostasis, but they are now also considered to be comp
65 ort broad physiological functions, including haemostasis, calcium homeostasis, immune response and en
66 of the equilibrium between all components of haemostasis (coagulation, anticoagulation, fibrinolysis,
67                                     Impaired haemostasis could exacerbate the primary insult with ris
68  the International Society on Thrombosis and Haemostasis criteria for major bleeding.
69 ing International Society for Thrombosis and Haemostasis criteria was 2/1421 (0.1% [0%-0.5%]).
70 nts (International Society on Thrombosis and Haemostasis criteria) at 6 months.
71 ing (International Society of Thrombosis and Haemostasis criteria), cause-specific hospitalization, a
72 g to International Society on Thrombosis and Haemostasis criteria, assessed in all patients who took
73 d by International Society on Thrombosis and Haemostasis criteria.
74 fied International Society of Thrombosis and Haemostasis criteria.
75 2005 International Society on Thrombosis and Haemostasis criteria.
76  and International Society on Thrombosis and Haemostasis-defined major bleeding (safety).
77 fied International Society on Thrombosis and Haemostasis definition).
78 g to International Society on Thrombosis and Haemostasis definition).
79                                       Normal haemostasis depends on an intricate balance between mech
80 s encoding seven clusters or isoforms of the haemostasis-disruptive C-type lectin (CTL) proteins from
81  improved survival with better management of haemostasis early after injury.
82  the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal,
83 de a locally inducible treatment to maintain haemostasis for haemophilia A.
84  size of the vascular access and the lack of haemostasis found in the study.
85  and suggest that selective pressure altered haemostasis genes to help Komodo dragons evade the antic
86 elet-like structures for the augmentation of haemostasis have focused solely on recapitulating aspect
87 l, platelets, and the coagulation cascade in haemostasis, highlighting the most recent advances in pl
88 lar efficacy to chrysin in the modulation of haemostasis in mice.
89  plasma for rapid INR reversal and effective haemostasis in patients needing VKA reversal for urgent
90 ts antithrombin with the goal of rebalancing haemostasis in people with haemophilia A or haemophilia
91 erapeutic, targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia
92                                              Haemostasis in the arteriolar circulation mediated by vo
93 nd Factor (vWF), a glycoprotein essential to haemostasis in Weibel-Palade bodies (WPBs), cigar-shaped
94 ave revealed key differences associated with haemostasis, innate immune system, lipid metabolism and
95                 Accurate assessment of blood haemostasis is essential for the management of patients
96                                              Haemostasis is governed by a highly complex system of in
97             A major age-associated change in haemostasis is the increase in von Willebrand factor (VW
98 fied International Society on Thrombosis and Haemostasis (ISTH) major bleeding (2.72% vs. 2.58%, P =
99 ath, International Society on Thrombosis and Haemostasis (ISTH) major or fatal bleeding, and all-caus
100  the International Society of Thrombosis and Haemostasis (ISTH) registry were obtained in August, 201
101  the International Society on Thrombosis and Haemostasis (ISTH) was a secondary safety outcome.
102 ) or International Society on Thrombosis and Haemostasis major bleeding (P-interaction, 0.73) on the
103 with International Society on Thrombosis and Haemostasis major bleeding a secondary safety outcome.
104 ated International Society on Thrombosis and Haemostasis major bleeding at 72 hours post-treatment an
105  and International Society on Thrombosis and Haemostasis major bleeding were increased with rivaroxab
106 more International Society on Thrombosis and Haemostasis major bleeding with clopidogrel use >30 days
107 more International Society on Thrombosis and Haemostasis major bleeding within 365 days (hazard ratio
108 /SE, International Society on Thrombosis and Haemostasis major bleeding, and the net clinical outcome
109 bral International Society on Thrombosis and Haemostasis major bleeding; and 5: cardiovascular hospit
110  was International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleedi
111 is demographic shift has profound effects on haemostasis, notably a progressive tilt towards a hyperc
112 ameter of used introducer sheath and lack of haemostasis observed (Fisher-Freeman-Halton test; p = 0.
113                                              Haemostasis occurs at sites of vascular injury, where fl
114        Nrf2 plays an important role in redox haemostasis of skeletal muscle in response to the increa
115                                              Haemostasis (platelet function) has been linked to the e
116 ion to being the chief cellular effectors of haemostasis, platelets are innate inflammatory cells tha
117 ur current knowledge of platelet function in haemostasis, possible mechanisms for aberrant activity i
118                                              Haemostasis refers to the physiological process aimed at
119                            Monitoring of the haemostasis status is significant for proper therapeutic
120           ATC is an endogenous impairment of haemostasis that begins at the moment of injury.
121                   Platelets are critical for haemostasis, thrombosis, and inflammatory responses, but
122 l roles in many cellular processes including haemostasis, thrombosis, inflammation and angiogenesis.
123 yeloid/lymphoid/compound white cells) and 49 haemostasis traits (including clotting cascade factors a
124 alization, inflammation, hypoxia, apoptosis, haemostasis, vasoconstriction and, finally, repair and r
125 used with ASO-FII mFFP demonstrated inferior haemostasis versus those transfused with ASO-FII followi
126 t play essential roles in the maintenance of haemostasis via blood clotting.
127                                    Effective haemostasis was achieved in 78 (90%) patients in the 4F-
128 demiological evidence, the mechanism linking haemostasis with early brain pathophysiology remains unc

 
Page Top